Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Stage 5 chronic kidney disease, Nephritis, Reduced kidney function (renal insufficiency), and Microscopic hematuria and 3 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 6 | Stage 5 chronic kidney disease, Nephritis, Reduced kidney function (renal insufficiency) |
Biomarker and diagnostic research for autosomal dominant progressive nephropathy with hypertension has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include gene therapy. Research is primarily sponsored by academic and government institutions.
177 publications have been identified in PubMed for autosomal dominant progressive nephropathy with hypertension. Kisho has analyzed 91 by research type. Research spans Review / Meta-Analysis (41%), Case Report / Case Series (15%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 37 |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 10:40 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Heart and blood vessels
1 |
Hypertension |
Lab test results | 1 | Elevated creatinine (kidney function marker) (elevated circulating creatinine concentration) |
Patient case studies | 14 | 15% |
Laboratory research | 14 | 15% |
Disease patterns and progression | 14 | 15% |
Clinical study results | 5 | 5% |
Testing and diagnosis research | 4 | 4% |
New treatment approaches | 3 | 3% |
Sampath Kumar D (2026). [PMID: 41782702](https://pubmed.ncbi.nlm.nih.gov/41782702/). *Clin Nephrol Case Stud*. [Case Report / Case Series]
Wu J (2026). [PMID: 41916891](https://pubmed.ncbi.nlm.nih.gov/41916891/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Review / Meta-Analysis]
Tang S (2026). [PMID: 41606608](https://pubmed.ncbi.nlm.nih.gov/41606608/). *J Transl Med*. [Review / Meta-Analysis]
Huang C (2026). [PMID: 41563237](https://pubmed.ncbi.nlm.nih.gov/41563237/). *J Am Soc Nephrol*. [Basic Science / Preclinical]
Gitomer BY (2026). [PMID: 41077128](https://pubmed.ncbi.nlm.nih.gov/41077128/). *Kidney Int*. [Clinical Trial Publication]
Lo Re C (2026). [PMID: 41243004](https://pubmed.ncbi.nlm.nih.gov/41243004/). *Pediatr Nephrol*. [Review / Meta-Analysis]
Birznieks CL (2026). [PMID: 41911082](https://pubmed.ncbi.nlm.nih.gov/41911082/). *Kidney Blood Press Res*. [Clinical Trial Publication]
Portakal O (2026). [PMID: 41645676](https://pubmed.ncbi.nlm.nih.gov/41645676/). *J Clin Lab Anal*. [Case Report / Case Series]
D'Amico S (2026). [PMID: 41507385](https://pubmed.ncbi.nlm.nih.gov/41507385/). *Sci Rep*. [Basic Science / Preclinical]
Subhash S (2026). [PMID: 41569965](https://pubmed.ncbi.nlm.nih.gov/41569965/). *Kidney Blood Press Res*. [Review / Meta-Analysis]